NTRK gene amplification in patients with metastatic cancer
Authors:
- Joon Oh ParkJPJoon Oh Park
Open Access
- 30 September 2017
- journal article
- Published by Sungkyunkwan University School of Medicine in Precision and Future Medicine
- Vol. 1 (3) , 129-137
Abstract
Purpose: Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are available on the effects of NTRK gene amplification. Methods: Samples from patients enrolled in the sequencing program were analyzed using a next-generation sequencing (NGS) cancer panel. For cases in which NTRK amplification (defined as ≥ 4.0 copies) was identified, panTRK immunohistochemical (IHC) staining of tissue microarrays was performed. Results: A total of 1,250 tumor specimens collected between February 2014 and January 2016 were analyzed using the NGS cancer panel. NTRK amplification was detected in 28 cases of various types of cancer. Among 27 cases, only four were positive for pan-TRK IHC. These four cases were melanoma, sarcoma, lung cancer, and gastric cancer. We found that 2.2% of cancer patients showed NTRK amplification using NGS cancer panel and NTRK amplification resulted in protein overexpression in 14.8% of these patients. Conclusion: Patients with NTRK amplification and increased TRK protein expression may be considered for inclusion in clinical trials for NTRK inhibitors.Keywords
This publication has 30 references indexed in Scilit:
- Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101Pediatric Blood & Cancer, 2016
- HER2 mRNA Status Contributes to the Discrepancy Between Gene Amplification and Protein Overexpression in Gastric CancerDigestive Diseases and Sciences, 2013
- Clinical significance of NTRK family gene expression in neuroblastomasPediatric Blood & Cancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Rearrangements of NTRK1 gene in papillary thyroid carcinomaMolecular and Cellular Endocrinology, 2010
- Developing c-MET pathway inhibitors for cancer therapy: progress and challengesTrends in Molecular Medicine, 2010
- RET and NTRK1 proto‐oncogenes in human diseasesJournal of Cellular Physiology, 2003
- Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGFNature, 1991
- A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequencesNature, 1986
- Oncogenes in solid human tumoursNature, 1982